(2

Ketamine N-methyl-d-aspartate receptors antidepressant hydroxynorketamine long-term potentiation

Journal

Brain and neuroscience advances
ISSN: 2398-2128
Titre abrégé: Brain Neurosci Adv
Pays: United States
ID NLM: 101702599

Informations de publication

Date de publication:
Historique:
received: 01 05 2020
accepted: 20 08 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 23 10 2020
Statut: epublish

Résumé

The ketamine metabolite (2

Identifiants

pubmed: 33088919
doi: 10.1177/2398212820957847
pii: 10.1177_2398212820957847
pmc: PMC7545754
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2398212820957847

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Références

Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Neuropharmacology. 2017 Jan;112(Pt A):144-149
pubmed: 27520396
J Neurosci. 2009 Mar 4;29(9):2774-9
pubmed: 19261873
Pharmacol Rev. 2018 Jul;70(3):621-660
pubmed: 29945898
Mol Brain. 2020 Jun 16;13(1):92
pubmed: 32546197
Neuropharmacology. 2018 Nov;142:30-40
pubmed: 29885421
Neuropsychopharmacology. 2018 Jan;43(1):221-222
pubmed: 29192654
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169
pubmed: 30796190
J Physiol. 1983 Jan;334:33-46
pubmed: 6306230
Nature. 2018 Feb 14;554(7692):317-322
pubmed: 29446381
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
Biol Psychiatry. 2017 Apr 15;81(8):e65-e67
pubmed: 27817845
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
Brain Res. 1983 Jan 3;258(1):159-64
pubmed: 24010182
Br J Pharmacol. 1983 Jun;79(2):565-75
pubmed: 6317114

Auteurs

Heather Kang (H)

Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
School of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Korea.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
Department of Physiology, University of Toronto, Toronto, ON, Canada.

Pojeong Park (P)

Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
School of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Korea.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
Department of Physiology, University of Toronto, Toronto, ON, Canada.

Muchun Han (M)

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
Department of Physiology, University of Toronto, Toronto, ON, Canada.

Patrick Tidball (P)

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.

John Georgiou (J)

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.

Zuner A Bortolotto (ZA)

Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.

David Lodge (D)

Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.

Bong-Kiun Kaang (BK)

School of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul, Korea.

Graham L Collingridge (GL)

Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.
Department of Physiology, University of Toronto, Toronto, ON, Canada.
TANZ Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.

Classifications MeSH